Want to see BBOT full AI Analyst Report?
BBOT Stock Chart & Stats
$12.59
--
Market closed
$12.59
--
Day’s Range― - ―
52-Week Range$7.00 - $14.87
Previous CloseN/A
VolumeN/A
Average Volume (3M)344.97K
Market Cap
$740.01M
Enterprise Value-$222.59
Total Cash (Recent Filing)$225.71M
Total Debt (Recent Filing)$2.51M
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Nov 18, 2026EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-709.70
Shares Outstanding80,174,270
10 Day Avg. Volume232,276
30 Day Avg. Volume344,973
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.95
Price to Sales (P/S)0.00
P/FCF Ratio-3.41
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$23.25Price Target Upside84.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.49
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low debt and a sizable equity base give BBOT structural financial flexibility to fund clinical programs and absorb timing variability in development. This durable balance sheet strength reduces bankruptcy risk and supports continued R&D spend, improving the company's ability to reach clinical inflection points.
Leadership Overhaul To Sharpen ExecutionA deliberate management reshuffle positions experienced drug development and strategy leaders at the helm as the portfolio advances. Over time, clearer accountability and fresh operational focus can improve trial execution, partner interactions, and milestone delivery—critical for a clinical‑stage biotech's durable execution capability.
Focused Precision Oncology Pipeline ProgressingConcentrated expertise in genetically defined RAS and PI3Kα cancers, with assets moving into Phase 1b and combination studies, implies a clearer pathway to pivotal trials. This focused pipeline increases the structural upside potential if clinical readouts validate mechanisms in high unmet-need oncology niches.
Bears Say
Pre-revenue With Widening Net LossesBeing pre-revenue with escalating net losses means the company lacks operating cash generation and depends entirely on financing and clinical progress for survival. Structurally, this elevates execution and dilution risk: failed trials or delays can rapidly undermine long-term viability absent product revenues.
Heavy Operating Cash Burn And Negative Free Cash FlowSustained high operating cash burn necessitates frequent financings or partnerships. Negative free cash flow reduces runway and forces trade-offs between development programs and capital preservation. This structural cash consumption increases the probability of dilution or strategic compromises over the next several quarters.
Declining Equity And Deeply Negative ROEDeclining shareholders' equity alongside a very negative ROE signals ongoing capital erosion from operating losses. This persistent value depletion constrains the firm's ability to self-finance growth, raises governance scrutiny, and makes the company more vulnerable to dilution or unfavorable financing terms if clinical progress stalls.
BridgeBio Oncology Therapeutics News
BBOT FAQ
What was BridgeBio Oncology Therapeutics’s price range in the past 12 months?
BridgeBio Oncology Therapeutics lowest stock price was $7.00 and its highest was $14.87 in the past 12 months.
What is BridgeBio Oncology Therapeutics’s market cap?
BridgeBio Oncology Therapeutics’s market cap is $740.01M.
When is BridgeBio Oncology Therapeutics’s upcoming earnings report date?
BridgeBio Oncology Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 94 days.
How were BridgeBio Oncology Therapeutics’s earnings last quarter?
BridgeBio Oncology Therapeutics released its earnings results on Aug 11, 2026. The company reported -$0.705 earnings per share for the quarter, missing the consensus estimate of -$0.565 by -$0.14.
Is BridgeBio Oncology Therapeutics overvalued?
According to Wall Street analysts BridgeBio Oncology Therapeutics’s price is currently Undervalued.
Does BridgeBio Oncology Therapeutics pay dividends?
BridgeBio Oncology Therapeutics does not currently pay dividends.
What is BridgeBio Oncology Therapeutics’s EPS estimate?
BridgeBio Oncology Therapeutics’s EPS estimate is -0.69.
How many shares outstanding does BridgeBio Oncology Therapeutics have?
BridgeBio Oncology Therapeutics has 80,174,270 shares outstanding.
What happened to BridgeBio Oncology Therapeutics’s price movement after its last earnings report?
BridgeBio Oncology Therapeutics reported an EPS of -$0.705 in its last earnings report, missing expectations of -$0.565. Following the earnings report the stock price went up 2.391%.
Which hedge fund is a major shareholder of BridgeBio Oncology Therapeutics?
Currently, no hedge funds are holding shares in BBOT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BridgeBio Oncology Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.25 (84.67% Upside)
$23.25 (84.67% Upside)
Blogger Sentiment
Bullish
BBOT Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 9.7%
Last 30 Days ▼ 9.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.62%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
90.84%
Trailing 12-Months
Company Description
BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
BBOT Stock 12 Month Forecast
Average Price Target
$23.25
▲(84.67% Upside)
Technical Analysis
Puma Biotechnology
―
CytomX Therapeutics
―
Kura Oncology
―
Zentalis Pharmaceuticals
―
C4 Therapeutics
―
Ownership Overview
40.70% Insiders
3.36% Mutual Funds
7.65% Other Institutional Investors
43.89% Public Companies and
Individual Investors